| Kaplan Meier Estimates | ||||
---|---|---|---|---|---|
5-Year Absence of Hepatic Decompensation (%) | Â | After Propensity Score Matching | |||
 | Metformin | Metformin + SGLT2-I | P | HR (95%CI) | |
All |  | 87.62 | 92.22 | 0.017 | 0.63 (0.43–0.93) |
Subgroup a | Â | Â | Â | Â | Â |
 Men |  | 87.42 | 87.78 | 0.477 | 0.83 (0.51–1.37) |
 Women |  | 88.72 | 96.02 | 0.086 | 0.57 (0.29–1.09) |
 White |  | 87.43 | 92.51 | < 0.01 | 0.49 (0.31–0.76) |
 Non-White |  | 93.05 | 94.31 | 0.105 | 0.43 (0.15–1.23) |
 Hispanic |  | 91.82 | 98.4 | 0.230 | 0.39 (0.08–1.92) |
 Non-Hispanic |  | 87.84 | 91.53 | 0.185 | 0.73 (0.46–1.16) |
 Age 39–59 |  | 94.86 | 95.08 | 0.708 | 1.18 (0.51–2.7) |
 Age 60–80 |  | 85.84 | 90.98 | < 0.01 | 0.53 (0.33–0.85) |
MASH b |  | 95.39 | 97.43 | 0.124 | 0.52 (0.22–1.22) |